Ovarian Cancer
Conditions
Interventions
experimental group:Nab-Paclitaxel plus Carboplatin
control group:Paclitaxel plus Carboplatin
Sponsors
the First Hospital of Jilin University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Aged >= 18 years , = 1.5*10^9/L, Platelet count >= *10^9/L, Hemoglobin >= 9.0 g/dL; Adequate liver function indicated by all of the following: Serum bilirubin = 40 mL/min. 6) Patients with >= 1 measurable disease; 7) Signed Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1) There is brain metastasis; 2) Uncontrolled severe medical conditions that the investigator believes will affect the subject's treatment with the study protocol: Dementia, change of mental state or any mental illness that would prevent understanding or informed consent or the completion of a questionnaire; 3) A history of allergy or hypersensitivity to any therapeutic ingredient; 4) Malignant tumors other than OV within 5 years, except basal cell or squamous cell skin cancer that is adequately treated, and ductal carcinoma in situ after radical surgery; 5) Subjects with peripheral neuropathy >=2 according to CTCAE V 5.0; 6) HBsAg positive subjects with peripheral blood HBV DNA titer >=1x10^3 IU/mL; 7) Hepatitis C virus (HCV) antibody positive or human immunodeficiency virus (HIV) antibody positive; 8) Received systemic or surgical treatment for OV; 9) Has been treated with any other experimental drug or participated in another interventional clinical trial within 30 days of the screening period; 10) The researcher thinks it is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Remission Rate (ORR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progress Free Survival (PFS);Quanlity of Life (QoL); | — |
Countries
China
Contacts
Public ContactLiu Ziling
Cancer Center, the First Hospital of Jilin University
Outcome results
None listed